Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals Stock
A loss of -1.240% shows a downward development for Hikma Pharmaceuticals.
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | -1.240% | -3.743% | 0.884% | -15.463% | 3.750% | -24.545% | -37.466% |
| Viatris Inc. | 1.330% | -8.369% | -3.787% | 88.270% | 34.067% | 46.728% | 16.592% |
| Repligen Corp. | 2.170% | 12.019% | 11.929% | 43.897% | -1.739% | -11.282% | -35.115% |
| Opko Health Inc. | 2.680% | -2.542% | -10.156% | 10.619% | 5.485% | -35.262% | -63.492% |
Comments
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat
